Health Care · Biological Products, (No Diagnostic Substances)

EXEL Exelixis Inc SEC Filings & Insider Trading Activity 2026

company
CIK 93976777 filings

EXEL at a glance

Exelixis Inc (EXEL, SEC CIK 939767) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended January 2, 2026 (FY2025), Exelixis Inc (EXEL) reported revenue of $2.3 billion (up 7.0% from FY2024) and net income of $782.6 million. Diluted EPS was $2.78.
  • As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Exelixis Inc (EXEL) shares worth $7.3 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Beckerle Mary C on August 10, 2026 of 9,812 shares at $53.66 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.3B
+7.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
38 funds
$7.3B · −1 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Oct 2, 2026

Risk Factors

  • No material changes to risk factors disclosed in Fiscal 2025 Form 10-K
  • Carried-forward business risk: unidentified or currently immaterial risks may impair operations
  • Carried-forward financial risk: existing risks could materially adversely affect financial condition and results of operations

Management Discussion & Analysis

  • Total revenue $658.7M vs $597.8M YoY, up $60.9M
  • Net income $218.1M vs $193.6M YoY, with effective tax rate 22.9% vs 23.3%
  • Best product CABOMETYX revenue $603.2M vs $539.9M, up $63.3M
  • Cash, equivalents and securities $1.4B vs $1.7B at December 31, 2025
  • Operating cash flow $839.5M, stock repurchases $402.1M through September 30, 2026
  • Outlook: revenue may increase, while reimbursement pressure, tariffs and generic competition remain headwinds

AI summary of the EXEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Exelixis reported financial results for the quarter ended October 2, 2026
  • Corporate update included in Exhibit 99.1, the key source for detailed results and guidance

Item EX-99.1: Item EX-99.1

  • Q3 revenue $658.7M vs $597.8M, driven by cabozantinib product revenue of $604.9M
  • GAAP diluted EPS $0.85 vs $0.69, supported by 8.2% lower diluted shares from repurchases
Filed Sep 11, 2026Full analysis →

Item 8.01: Other Events

  • FDA review of zanzalintinib plus atezolizumab for metastatic colorectal cancer extended three months
  • Updated PDUFA action date: March 3, 2027
Filed Aug 31, 2026Full analysis →

Item 8.01: Other Events

  • Federal Circuit affirmed validity of three patents protecting Exelixis’ product
  • MSN generic launch blocked until January 15, 2030, subject to appeals and regulatory exclusivity

AI summaries of EXEL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for EXEL

Don't miss the next EXEL filing

  • Alerts as it files. A push when EXEL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut EXEL, by share count.
  • Ask anything. An AI agent that reads every EXEL filing and answers with sources.

EXEL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Beckerle Mary CSellAug 10, 2026$53.66
Beckerle Mary CAMay 27, 2026-
PAPADOPOULOS STELIOSAMay 27, 2026-
JOHNSON DAVID EDWARDAMay 27, 2026-
Freire Maria CAMay 27, 2026-
Oliver BobAMay 27, 2026-
POSTE GEORGEAMay 27, 2026-
WYSZOMIERSKI JACK LAMay 27, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.2B$2.3B
Operating Income-$604.6M$872.2M
Net Income$207.8M$521.3M$782.6M
Op. Margin-27.9%37.6%
Net Margin-24.0%33.7%
Balance Sheet
Total Assets$2.9B$2.9B$2.8B
Equity-$2.2B$2.2B
ROE-23.2%36.2%
Per Share
EPS$0.65$1.76$2.78
Cash Flow
Operating CF-$700.0M$884.3M
CapEx$40.5M$28.4M$8.4M

Source: XBRL data in Exelixis Inc (EXEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate EXEL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
EXEL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202638$7.28B
Q2 202639$6.99B
Q1 202638$5.56B
Q4 202533$5.62B
Q3 202536$5.19B
Q2 202533$5.70B
Q1 202532$3.45B
Q4 202427$2.87B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 276 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

EXEL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QOct 29, 2026Analysis
8-KOct 29, 2026Analysis-
8-KSep 11, 2026Analysis-
8-KAug 31, 2026Analysis-
4Aug 12, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
8-KMay 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 29, 2026-
4May 28, 2026-
4May 8, 2026-
4May 8, 2026-
4May 8, 2026-
4May 8, 2026-
8-KMay 5, 2026--
10-QMay 5, 2026-

Related Health Care companies

All Health Care →

EXEL SEC filings: frequently asked questions

Which institutions hold EXEL stock?

As of September 30, 2026, the largest Exelixis Inc (EXEL) holders among the 13F filers tracked by SignalX were BlackRock ($1.7 billion), Renaissance Technologies LLC ($747.2 million), Vanguard Portfolio Management LLC ($698.3 million), Vanguard Capital Management LLC ($628.4 million), State Street Corp ($614.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was EXEL's revenue in fiscal year 2025?

For the fiscal year ended January 2, 2026 (FY2025), Exelixis Inc (EXEL) reported revenue of $2.3 billion (up 7.0% from FY2024) and net income of $782.6 million. Diluted EPS was $2.78. The figures come from the XBRL data in the 10-K.

What did EXEL report in its latest 8-K?

Exelixis Inc (EXEL) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Exelixis reported financial results for the quarter ended October 2, 2026.

What are the latest EXEL SEC filings?

Exelixis Inc (EXEL) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on August 12, 2026.

What is EXEL's SEC CIK number?

Exelixis Inc (EXEL)'s SEC Central Index Key (CIK) is 939767. EDGAR lists every EXEL filing under that number.

Ask anything about EXEL

The research agent reads EXEL's filings, financials, insider trades and 13F holders, then answers with sources.